{"entity":{"id":"nct07204340","kind":"trial","name":"TLN-372 in Advanced KRAS Mutant Solid Tumors","aka":[],"tldr":"A phase 1 trial of TLN-372 run by Treeline Biosciences, Inc., now recruiting.","summary":"TLN-372 in Advanced KRAS Mutant Solid Tumors is a phase 1 interventional study registered as NCT07204340 by Treeline Biosciences, Inc., with 270 participants planned, started 2025-09-29. Conditions recorded: KRAS Mutant Solid Tumors. Interventions recorded: TLN-372, TLN-372 in combination with cetuximab and TLN-372 in combination with pembrolizumab.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07204340","url":"https://clinicaltrials.gov/study/NCT07204340"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tln-372"],"companies":["treeline-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07204340","phase":"1","setting":"An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors","sponsor":"Treeline Biosciences, Inc.","enrolled":270,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07204340/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"tln-372","kind":"drug","name":"TLN-372","route":"/drugs/tln-372/"}],"company":[{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","route":"/companies/treeline-biosciences/"}]}}